Chris Crawford, M. D.
NPI 1447248281 · Dermatology Physician · Plano, TX
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1447248281
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M. D.
- Sex
- Male
- Sole proprietor
- No
- License
- J7938 (TX)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
4,857 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 2,107 | $7 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 897 | $91 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 621 | $47 |
| Biopsy of Related Skin Growth, First Growth11102 | 502 | $94 |
| Biopsy of Related Skin Growth, Each Additional Growth11103 | 122 | $50 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Ketoconazole | 158 | 75 |
| Clobetasol Propionate | 150 | 91 |
| Triamcinolone Acetonide | 138 | 96 |
| Dupilumabbrand: Dupixent Pen | 50 | — |
| Fluorouracil | 44 | 43 |
| Metronidazole | 42 | 27 |
| Mupirocin | 41 | 32 |
| Desonide | 30 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$3,379 across 192 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-10-06
- Last updated
- 2025-08-05
- Certified
- 2025-08-05
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.